Table 1.
Characteristics of the patients under treatment in the initial real-world register collection
|
|
Other mode of actions | TNF inhibitor |
| N | 6067 | 40 767 |
| Disease duration (median (IQR) in year) | 9.8 (4.6, 17.9) | 7.4 (2.9, 14.6) |
| Treatment duration (median (IQR) in year) | 1.2 (0.5, 2.7) | 1.7 (0.6, 4.3) |
| Number of previous bDMARD (number (%)) | ||
| 0 | 1451 (23.9) | 23 016 (56.5) |
| 1 | 2019 (33.3) | 12 269 (30.1) |
| 2 | 1383 (22.8) | 3896 (9.6) |
| 3+ | 1214 (20.0) | 1586 (3.9) |
| Concomitant csDMARD (number (%)) | ||
| MTX | 2982 (49.2) | 20 062 (49.2) |
| MTX +other | 68 (1.1) | 1080 (2.6) |
| None | 1907 (31.4) | 15 047 (36.9) |
| Other | 1110 (18.3) | 4578 (11.2) |
| CDAI0 (median (IQR)) | 23.4 (16.5, 32.0) | 23.0 (13.9, 33.5) |
| CDAI12 (median (IQR)) | 10.0 (5.0, 17.3) | 7.0 (2.9, 14.0) |
| Treatment status (number (%)) | ||
| Ongoing | 3336 (55.0) | 24 968 (61.2) |
| Stopped for adverse event | 459 (7.6) | 1876 (4.6) |
| Stopped for ineffectiveness | 748 (12.3) | 3369 (8.3) |
| Stopped for pregnancy | 5 (0.1) | 53 (0.1) |
| Stopped for remission | 62 (1.0) | 189 (0.5) |
| Stopped for other | 313 (5.2) | 1089 (2.7) |
| Stopped for unspecified reason | 1144 (18.9) | 9223 (22.6) |
| Missing CDAI12 (number (%)) | 1680 (27.7) | 9415 (23.1) |
| Number (%) of patients stopping after 1 year (number (%)) | 1017 (16.8) | 6081 (14.9) |
| LDA at 12 month (number (%)) | 1811 (51.4) | 15 873 (63.7) |
Number of observations (N), number and proportion of patients having 0, 1, 2, 3 and more (3+) previous biological DMARD, of patient having methotrexate alone (MTX), methotrexate with other csDMARD (MTX +other), at least an csDMARD other than MTX (other) or no concomitant synthetic DMARD treatment (none), median (IQR) value of baseline CDAI (CDAI0) and CDAI at 12 months (CDAI12).
CDAI, Clinical Disease Activity Index; csDMARD, conventional synthetic disease-modifying antirheumatic drugs; TNF, tumour necrosis factor.